Daphnetin ameliorates experimental colitis by modulating microbiota composition and T_reg/T_h17 balance

Area of Science:

• Gastroenterology and Immunology
• Microbiome Research
• Pharmacology

Background:

• Inflammatory bowel diseases (IBD) involve chronic gut inflammation and dysbiosis.
• Manipulating gut microbiota is a therapeutic strategy for IBD.
• Daphnetin (DAPH), a coumarin derivative, possesses anti-inflammatory properties.

Purpose of the Study:

• To investigate the efficacy of Daphnetin (DAPH) in ameliorating experimental colitis.
• To explore the mechanisms underlying DAPH's effects, focusing on gut microbiota and immune modulation.

Main Methods:

• Dextran sulfate sodium (DSS)-induced colitis model in mice.
• Analysis of gut microbiota composition and metabolic profiles.
• Assessment of T regulatory (Treg) and T helper 17 (Th17) cell differentiation.
• Cohousing and fecal microbiota transplantation (FMT) experiments.

Main Results:

• DAPH treatment alleviated colitis, reduced inflammation, and improved intestinal integrity.
• DAPH modulated gut microbiota, increasing short-chain fatty acid (SCFA)-producing bacteria.
• Increased SCFA-producing bacteria correlated with enhanced Treg cell development and reduced Th17 cell differentiation.
• DAPH's protective effects were transferable via cohousing and FMT.

Conclusions:

• Daphnetin (DAPH) ameliorates experimental colitis by modulating gut microbiota composition and restoring immune homeostasis.
• The therapeutic effects of DAPH are mediated, in part, by promoting SCFA-producing bacteria, which influence Treg/Th17 balance.
• DAPH shows potential as a therapeutic agent for IBD, with implications for microbiome-targeted therapies.